First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors.

被引：5
|
作者：
Shimizu, Toshio
Doi, Toshihiko
Kondo, Shunsuke
Takahashi, Hideaki
Yamamoto, Noboru
Sheldon-Waniga, Emily
Zhou, Xiaofei
Bahamon, Brittany
Li, Hongmei
Kuboki, Yasutoshi
机构：
[1] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[3] Natl Canc Ctr, Dept Internal Med, Tokyo, Japan
[4] Natl Canc Ctr Hosp East, Dept Expt Therapeut, Kashiwa, Chiba, Japan
[5] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[6] Millennium Pharmaceut Inc, Cambridge, MA USA
[7] Takeda Pharmaceut Co Ltd, Cambridge, MA USA
[8] Natl Canc Ctr Hosp East, Gastrointestinal Oncol Div, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2506
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
    Kuboki, Yasutoshi
    Shimizu, Toshio
    Yonemori, Kan
    Kojima, Takashi
    Kondo, Shunsuke
    Koganemaru, Shigehiro
    Iwasa, Satoru
    Harano, Kenichi
    Koyama, Takafumi
    Lu, Vickie
    Zhou, Xiaofei
    Niu, Huifeng
    Yanai, Tomoko
    Garcia-Ribas, Ignacio
    Doi, Toshihiko
    Yamamoto, Noboru
    [J]. CANCER RESEARCH COMMUNICATIONS, 2022, 2 (11): : 1426 - 1435
  • [2] Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors
    Zhou, Xiaofei
    Ouerdani, Aziz
    Diderichsen, Paul Matthias
    Gupta, Neeraj
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (03): : 422 - 433
  • [3] Assessment of Effects of Investigational TAK-931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors
    Zhou, Xiaofei
    Diderichsen, Paul Matthias
    Gupta, Neeraj
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (06): : 770 - 779
  • [4] Translational pharmacokinetic-pharmacodynamic xenograft model for TAK-931, a small molecule cell division cycle 7 (CDC7) kinase inhibitor
    Locuson, Charles
    Patel, Mayank
    Ohashi, Akihiro
    Iwai, Kenichi
    Nambu, Tadahiro
    Takeuchi, Toshiyuki
    Kogame, Akifumi
    Bowman, Douglas
    Tirrell, Stephen
    Niu, Huifeng
    Xia, Cindy
    [J]. CANCER RESEARCH, 2017, 77
  • [5] A CRUK first-in-human phase I trial of LY3143921, a novel CDC7 inhibitor, in patients with advanced solid tumors.
    Gallagher, Peter F.
    Naylor, Gregory
    Bashir, Saira
    Yan, Xiangfei
    Burke, David
    Plummer, Elizabeth Ruth
    Evans, T. R. Jeffry
    Coyle, Victoria M.
    Clive, Sally
    McGuigan, Lesley
    Heinzmann, Kathrin
    Halbert, Gavin
    Veal, Gareth
    Tiplady, Eleanor
    Barnett, Shelby
    Yalla, Krishna
    Brook, Sue
    Dobbs, Nicola
    Wilson, Richard H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] A CRUK first-in-human phase I trial of a CDC7 Inhibitor, LY3143921 hydrate, in patients with advanced solid tumors.
    Gallagher, Peter F.
    Coyle, Victoria
    Evans, T. R. Jeffry
    Plummer, Elizabeth Ruth
    Clive, Sally
    McGuigan, Lesley
    Roxburgh, Patricia
    Haris, Noor Md
    Symeonides, Stefan N.
    Naylor, Gregory
    Bashir, Saira
    Stanley, Barbara
    Godfrey, Lisa
    Elliott, Moira
    Halbert, Gavin
    Brook, Sue
    Dobbs, Nicola
    Wilson, Richard H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Identification of the predictive biomarker signatures for TAK-931, a CDC7 inhibitor, in a preclinical phase 2-like study
    Shin, H.
    Koenig, E.
    Nambu, T.
    Yu, J.
    Zhang, M.
    Kannan, K.
    Lightcap, E.
    Ohashi, A.
    Niu, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 103 : E99 - E100
  • [8] Pharmacokinetics of the CDC7 inhibitor LY3143921 hydrate, a CRUK first-in-human phase I trial in patients with advanced solid tumors
    Barnett, Shelby
    Griffin, Melanie
    Wilson, Richard H.
    Plummer, Elizabeth R.
    Evans, Jeffry T.
    Coyle, Victoria
    Clive, Sally
    Godfrey, Lisa
    Dobbs, Nicola
    McGuigan, Lesley
    Brook, Sue
    Halbert, Gavin
    Veal, Gareth J.
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [9] A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Patel, Manish R.
    Yap, Timothy A.
    McEachern, Kristen
    Kuplast-Barr, Kristy
    Utley, Luke
    Cleary, Lisa
    Manyak, Erika
    Bozon, Viviana
    Parasuraman, Sudha
    Johnson, Melissa Lynne
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.
    El-Khoueiry, Anthony B.
    Ning, Yan
    Yang, Dongyun
    Cole, Sarah
    Kahn, Michael
    Zoghbi, Marwan
    Berg, Jennifer
    Fujimori, Masamoto
    Inada, Tetsuhi
    Kouji, Hiroyuki
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345